Sinaptica Looks to Treat Alzheimer's Disease Symptoms with Device
Sinaptica said it has won breakthrough device designation for its SinaptiStim technology.
Stay updated with breaking news from Device Designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sinaptica said it has won breakthrough device designation for its SinaptiStim technology.
The neurostimulation device, which is currently for investigational use only, aims to treat cognitive and functional decline in Alzheimer's patients.
Genomic testing company Variantyx raised $20 million in debt financing, and mental health provider Mindful Care scooped up $7 million.
Viome Life Sciences, a mission-driven digital health company, announced additional $67M funding toward its Series C round.
PRINCETON, N.J., Oct. 12, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions i...